Russia claims second vaccine is 100% effective – Radio Report 3

Russian health officials said on Tuesday that the country’s second vaccine developed against the coronavirus, EpiVacCorona, demonstrated 100% immunological efficacy, something never announced by any of the other candidates in the world.

The person responsible for disseminating the information was the Rospotrebnadzor, the national health agency. “The effectiveness of the vaccine lies in its immunological and preventive effectiveness. Based on the results of Phase 1 and 2 clinical trials of the EpiVacCorona vaccine, the production of specific antibodies were produced in all volunteersReads the brief statement from the entity, adding that results will be presented in February.

/ Embedded code reception /

/ End of embed code /

This vaccine, which was not purchased by Argentina, is developed by the scientific center of virology and biotechnology Véktor and is based on peptide antigens. It was registered in mid-October, and in November the Russian health ministry authorized the manufacturer to perform tests on 3,000 volunteers and people over 60 years old.

Learn, recognize and neutralize the virus

Last December, Russian Deputy Prime Minister Tatiana Golikova spoke of this development: “Unlike the first Russian vaccine Sputnik V, which is a vector vaccine, that is to say produced from adenovirus, the new vaccine was built on a promising synthetic platform, is a peptide vaccine, consists of short fragments of artificially synthesized viral proteins called peptides, which the immune system learns, then recognizes and neutralizes. I must say that the vaccine is characterized by the absence of reactogenicity and a sufficiently high level of safety, ”said the official.

For his part, the CEO of Véktor, Rinat Maksyutov, added that “the expected advantage of this vaccine compared to other vaccine platforms is the efertility against strains with antigenic evolution, because it contains conservative SARS-COV-2 epitopes “.

Maksyutov added that it was a “very safe vaccine, easy to produce and it has stability in its components, providing an advantage when stored or transported to vaccination units “.

In early December, Russian health authorities provided the World Health Organization (WHO) with documents on EpiVacCorona for analysis.

Finally on Monday, before the information on the effectiveness of the vaccine is known, the Russian Deputy Prime Minister confirmed that the mass production of the EpiVacCorona will be launched in February 2021, according to the Tass agency.

Timeline of EpiVacCorona and other Russian vaccines

– The development of the EpiVacCorona began on July 24, 2020, when the scientific center of virology and biotechnology Véktor received a permit from the Ministry of Health from Russia to conduct clinical trials of its coronavirus vaccine in volunteers.

– The first volunteer was inoculated on July 27 and clinical trials of the vaccine were completed on September 30. Following this, President Vladimir Putin announced on October 14 that the vaccine developed by Véktor had been recorded.

– A third Russian vaccine, called ChuVac, which is being developed by the Chumakov center, has already passed its first two test steps in volunteers and could be produced in series from February.

– Ural, from the company Medsintez, is the fourth Russian vaccine in chronological order and has recently entered the preclinical testing phase. The first results of the survey will be published in February.

Report by Marcos Calligaris.